BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1084 related articles for article (PubMed ID: 26026972)

  • 1. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
    de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital.
    Kader AA; Kumar A
    Ann Saudi Med; 2005; 25(3):239-42. PubMed ID: 16119526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan.
    Liao CH; Sheng WH; Wang JT; Sun HY; Wang HK; Hsueh PR; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2006 Feb; 39(1):59-66. PubMed ID: 16440125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS; García JA; Muñoz JL
    Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric community acquired urinary tract infections due to extended-spectrum beta-lactamase versus non-extended-spectrum beta-lactamase producing bacteria.
    Alsubaie MA; Alsuheili AZ; Aljehani MN; Alothman AA; Alzahrani AS; Mohammedfadel HA; Alnajjar AA
    Pediatr Int; 2023; 65(1):e15620. PubMed ID: 37735838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of antibiotic resistance among urine isolates of Escherichia coli in the community, despite a major hospital outbreak with Klebsiella pneumoniae producing CTX-M-15 in Uppsala County.
    Lindbäck H; Lindbäck J; Sylvan S; Melhus A
    Scand J Infect Dis; 2010 Apr; 42(4):243-8. PubMed ID: 20085420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive
    Park KS; Kim DR; Baek JY; Shin A; Kim KR; Park H; Son S; Cho H; Kim YJ
    J Korean Med Sci; 2023 Dec; 38(48):e361. PubMed ID: 38084025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia.
    Kader AA; Angamuthu K
    Saudi Med J; 2005 Jun; 26(6):956-9. PubMed ID: 15983682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.
    de Cueto M; López L; Hernández JR; Morillo C; Pascual A
    Antimicrob Agents Chemother; 2006 Jan; 50(1):368-70. PubMed ID: 16377714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period.
    Burgess DS; Hall RG; Lewis JS; Jorgensen JH; Patterson JE
    Pharmacotherapy; 2003 Oct; 23(10):1232-7. PubMed ID: 14594340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and antimicrobial susceptibility of extended-spectrum beta lactamases-producing
    Mofolorunsho KC; Ocheni HO; Aminu RF; Omatola CA; Olowonibi OO
    Afr Health Sci; 2021 Jun; 21(2):505-512. PubMed ID: 34795702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings.
    Khanfar HS; Bindayna KM; Senok AC; Botta GA
    J Infect Dev Ctries; 2009 May; 3(4):295-9. PubMed ID: 19759493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characterization of ESBL-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urine of nonhospitalized patients in the Zagreb region].
    Marijan T; Plecko V; Vranes J; Dzepina AM; Bedenić B; Kalenić S
    Med Glas (Zenica); 2010 Feb; 7(1):46-53. PubMed ID: 20387724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes.
    Apisarnthanarak A; Kiratisin P; Mundy LM
    Infect Control Hosp Epidemiol; 2008 Nov; 29(11):1026-34. PubMed ID: 18947321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.